ISSN 1662-4009 (online)

ey0015.6-9 | New hope | ESPEYB15

6.9 Fertility Preservation for Transgender Adolescents

D Chen , L Simons , EK Johnson , BA Lockart , C Finlayson

To read the full abstract: J Adolesc Health. 2017 Jul;61(1):120-123Recent developments in assisted reproduction technologies (ART) have changed the scene for fertility wishes in a number of disorders, including GD. Fertility preservation is now routinely offered to postpubertal adolescent and adult GD patients at increasing numbers of medical centers. For biological boys, this is a non...

ey0021.10-11 | New Insights | ESPEYB21

10.11. Childhood-onset type 1 diabetes and subsequent adult psychiatric disorders: a nationwide cohort and genome-wide Mendelian randomization study

T Formanek , D Chen , Z Šumnik , K Mlada , J Hughes , S Burgess , al. et

Brief Summary: This study explored the potential causal pathways underlying the association between childhood-onset T1D and subsequent psychiatric disorders, using data from a Czech national register of 4,500 children (age ≤14 years) with type 1 diabetes (T1D) and large-scale European genetic studies. Children diagnosed with T1D had an elevated risk of developing substance use, mood, anxiety and personality disorders, and behavioural syndromes. In contrast, they had a lo...

ey0020.4-11 | Psychological Effects of Hormone Treatments | ESPEYB20

4.11. Psychosocial functioning in transgender youth after 2 years of hormones

D Chen , J Berona , YM Chan , D Ehrensaft , R Garofalo , MA Hidalgo , SM Rosenthal , AC Tishelman , J Olson-Kennedy

Brief summary: A four centre prospective longitudinal study of 315 transgender and non-binary adolescents in the USA showed improvement in gender congruence and appearance and some reduction of depression and anxiety (but not in birth-registered males) after 2 years of gender affirming hormone (GAH) treatment.The race is on to provide clear evidence to support hormonal intervention for transgender adolescents. This longitudinal study employed a number of...

ey0019.12-11 | Hyperlipidemia | ESPEYB19

12.11. Identification and evaluation of a lipid-lowering small compound in preclinical models and in a Phase I trial

H. Wang J, Zhao J, Yan C, Xi C, Wu C, Zhao J, Li F, Ding Y, Zhang R, Qi S, Li X, Liu C, Hou W, Chen H, Wang Y, Wu D, Chen K, Jiang H, Huang H, Liu

Cell Metabolism 2022;34(5):667-80.e6. doi: 10.1016/j.cmet.2022.03.006Brief Summary: In preclinical models and a phase 1 trial, a powerful new lipid small molecule was shown to act through a mechanism distinct from those of known hypolipidemic agents. Targeting HNF-1α may be a new therapeutic strategy.Comment: Familial hypercholesterolemia (FH) is the most common...

ey0020.8-15 | New Hopes | ESPEYB20

8.15. Exocrine pancreas regeneration modifies original pancreas to alleviate diabetes in mouse models

X Kou , J Liu , D Wang , M Yu , C Li , L Lu , C Chen , D Liu , W Yu , T Yu , Y Liu , X Mao , A Naji , T Cai , L Sun , S Shi

Brief summary: In this experimental study, pancreas-derived mesenchymal stem cells (PMSCs) were implanted into the kidney capsule of mice with streptozotocin (STZ)-induced diabetes. PMSCs led to increased levels of IL-6 in T-helper 1 and T-helper 17 cells, which transiently activated tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ), which in turn decreased levels of interleukin-17. This was associated with exocrine pancreas regeneration and rescue of ...